One of the largest Canadian licensed producers (LPs) issued on Tuesday (June 19) one of its last quarterly and fiscal reports as it prepares to complete an acquisition by another major LP.

MedReleaf (TSX:LEAF) provided its investors with a detailed look at its fourth quarter and fiscal 2018 financial results. The company reported close to over C$12 million in sales of dried cannabis and extract products during its fourth quarter, a period which ended on March 31.


During the entire fiscal 2018 period, MedReleaf reported C$43.6 million in sales, with extracts amounting to 18 percent of that result and bringing in C$8 million.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The company indicated it estimates sales of extracts will continue to grow in the overall revenue thanks to the introduction of novel products such as creams and soft gel capsules. These products amounted to C$2.4 million in sales during Q4, a 20 percent share of the total sales.

MedReleaf reported the sale of over five million total grams of cannabis were sold during its fiscal 2018 year and a little over 1.4 million during the quarter.

According to the report, as of March 31, the company held a C$215.9 million cash asset and working capital of C$255.7 million.

The report also accounted for a net loss of C$7.5 million during the twelve month period that ended on March 31.

“The decrease in net income and comprehensive income was primarily due to increased overhead expenses partially offset by increased sales and gross profit as the Company expanded production capacity, specifically driven by fair value gains experienced at Bradford Facility,” the company explained.

MedReleaf gets closer to the time to join Aurora

“I’m immensely proud of our achievements… and I am confident MedReleaf will bring tremendous value to Aurora, as we combine to create a preeminent global cannabis company,” MedReleaf’s CEO Neil Closner said in a statement.

In May, MedReleaf confirmed a purchase agreement with competitor and fellow TSX-listed LP Aurora Cannabis (TSX:ACB). The deal was set at a value of C$3.2 billion for the acquisition of all MedReleaf assets and stock.

Investors of MedReleaf will obtain 3.575 ACB common shares for each LEAF share held. The deal places a 34 percent premium on each LEAF share since it was set at a price of C$29.44 per share.

At the time Charles Taerk, president and CEO of Faircourt Asset Management, told the Investing News Network (INN) that, in his view, LEAF and ACB holders were the biggest winners of the entire transaction.

On the market analyst research aggregator site TipRanks, MedReleaf currently holds a “Moderate Buy” rating based on five analysts reviews.

After the public markets closed on Tuesday MedReleaf’s shares had increased in value by 4.35 percent and reached a price of C$27.82 per share.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that, in connection with the previously announced share consolidation on a thirty (30) for one (1) basis (the “Consolidation”), the Company will be changing its name to West Island Brands Inc. (the “Name Change”).

The common shares are scheduled to begin trading on a post-consolidation basis at market open on October 20, 2021 under the stock symbol “WIB”. The new CUSIP number will be 953400108 and the new ISIN number will be CA9534001081. Following the Consolidation, the Company will have approximately 10,712,484 common shares issued and outstanding.

Keep reading... Show less

In the cannabis space this week, a popular beverage maker hired a new executive in hopes of pursuing opportunities in the cannabis drink industry.

Meanwhile, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced a fresh acquisition agreement for a partner designed to boost its presence in a potentially available US adult-use cannabis market.

Keep reading... Show less

Via InvestorWireIBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, today announces that it will be collaborating with Microdose Psychedelic Insights for the Psych e delic Capital: October 2021 Conference which is set to be held in an entirely virtual format on Oct. 28, 2021.

The Psychedelic Capital: October Conference is set to be a virtual event, covering the most innovative and cutting-edge companies, latest IPOs, newest opportunities and deepest insights into the global psychedelic industry. From exploring ongoing governmental policy shifts to commercial product breakthroughs, the conference will serve to educate attendees on the potential uses and benefits attached to psychedelics in today’s environment.

Keep reading... Show less

 Adastra Holdings Ltd. (formerly Phyto Extractions Inc.) (CSE: XTRX) (FRA: D2EP) (“Adastra” or the “Company”) today announced positive operational and financial developments as the Company continues to pursue its mission to be a leader in the development and manufacture of pharma-quality, cannabis API and derivative products. These developments include record shipments in September, product portfolio expansion, and continued progress with Health Canada regarding its Controlled Substances Dealers License application.

Record September Shipments
Adastra shipped 68,272 consumer-packaged units and 20,000g of bulk extract in September compared to 41,571 units in September 2020 , a 64% increase year over year.

Keep reading... Show less

Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that, pursuant to a director’s resolution, the Company will be consolidating its issued and outstanding share capital on the basis of every thirty (30) old Common Shares being consolidated into one (1) new Common Share (the “Share Consolidation”). Any fractional shares remaining after giving effect to the Share Consolidation will be cancelled.

As a result, the outstanding Common Shares of the Company will be reduced to approximately 10,712,484. The Company has no other securities outstanding.

Keep reading... Show less